More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Fostriecin [87860-39-7]
Chemical Structure
Chemical Structure
Chemical Structure

Fostriecin [87860-39-7]

Research Use Only
AG-CN2-0057
AdipoGen Life Sciences
CAS Number87860-39-7
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>95%
Molecular Weight452.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Fostriecin [87860-39-7]
  • Delivery Days Customer
    10
  • CAS Number
    87860-39-7
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Hazard Information
    Warning
  • Molecular Formula
    C19H26O9PNa
  • Molecular Weight
    452.4
  • Scientific Description
    Antibiotic [1, 2, 18]. Anticancer compound [1-5, 8, 9, 11]. Antifungal [6]. Catalytic inhibitor of topoisomerase II (IC50 = 40 microM) [7, 16]. Potent protein phosphatase 2A (PP2A) (IC50 = 1.5 nM) and 4 (PP4) (IC50 = 3 nM) inhibitor [10, 12, 15]. Weak protein phosphatase type 1 (PP1) inhibitor (IC50=131microM). No apparent inhibition on PP2B [10, 12]. Mitotic entry checkpoint inhibitor [10]. Mediates cell cycle arrest at G2-M-phase [14]. Ischemia protective [13]. The PP2A binding site is different from that of okadaic acid [17, 19] - Chemical. CAS: 87860-39-7. Formula: C19H26O9PNa. MW: 452.4. Isolated from Streptomyces pulveraceous subsp. fostreus. Antibiotic. Anticancer compound. Antifungal. Catalytic inhibitor of topoisomerase II (IC50 = 40 microM). Potent protein phosphatase 2A (PP2A) (IC50 = 1.5 nM) and 4 (PP4) (IC50 = 3 nM) inhibitor. Weak protein phosphatase type 1 (PP1) inhibitor (IC50=131microM). No apparent inhibition on PP2B. Mitotic entry checkpoint inhibitor. Mediates cell cycle arrest at G2-M-phase. Ischemia protective. The PP2A binding site is different from that of okadaic acid
  • SMILES
    [Na+].C[C@@](O)(\C=C\[C@H]1CC=CC(=O)O1)[C@@H](C[C@@H](O)\C=C/C=C\C=C\CO)OP(O)([O-])=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties: J.B. Tunac, et al.; J. Antibiot. (Tokyo) 36, 1595 (1983)
  • Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization: S.S. Stampwala, et al.; J. Antibiot. (Tokyo) 36, 1601 (1983)
  • Studies on the biochemical mechanism of the novel antitumor agent, CI- 920: D.W. Fry, et al.; Cancer Chemother. Pharmacol. 13, 171 (1984)
  • Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues: W.R. Leopold, et al.; Cancer Res. 44, 1928 (1984)
  • In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay: W. Scheithauer, et al.; Eur. J. Cancer Clin. Oncol. 22, 921 (1986)
  • Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271: S.W. Mamber, et al.; J. Antibiot. (Tokyo) 39, 1467 (1986)
  • Inhibition of type II topoisomerase by fostriecin: T.J. Boritzki, et al.; Biochem. Pharmacol. 37, 4063 (1988)
  • Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells: M.A. Hotz, et al.; Cancer Res. 52, 1530 (1992)
  • Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation: M.A. Hotz, et al.; Exp. Cell Res. 201, 184 (1992)
  • Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A: M. Roberge, et al.; Cancer Res. 54, 6115 (1994)